Abstract
Interstitial pneumonia (IP) is a common and poor prognostic comorbidity in patients with non-small cell lung cancer (NSCLC) and is also a risk factor for pneumonitis. A phase II trial of atezolizumab for pretreated NSCLC patients with comorbid idiopathic IP (TORG1936/AMBITIOUS study) was terminated early due to the high incidence of severe pneumonitis. While safety information has already been published, we will report the results of the final analysis including efficacy and results of translational study.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call